CD274 and esophageal adenocarcinoma: Recently, nivolumab plus chemotherapy have been investigated in the first-line setting of advanced gastric, GEJ, or esophageal adenocarcinoma, which significantly prolonged OS and PFS compared with chemotherapy alone in patients with a PD-L1 CPS of five or more as well as in patients with a PD-L1 CPS of one or more and all randomly assigned patients [10].